• Pipeline Programs

Pipeline Programs

Blend has been highly productive in generating entirely new classes of platinum drugs as well as other novel molecules with superior therapeutic properties.

Blend’s pipeline includes platinum-based drugs, which are among the most powerful and widely used anticancer therapeutics in use today (see sidebar). Our two lead platinum development programs are: 

• new mono-functional platinum molecules with a novel mechanism of action
• new platinum molecules within nanoparticles

In addition, we are applying our proprietary approach to discover and develop other innovative drugs in our pipeline, including:

• additional targeted new molecules with novel modes of action
• combination therapy nanomedicines with optimized therapeutic profiles

Platinums with a Novel Mechanism and Improved Therapeutic Profiles

Platinum-based drugs are among the most effective anti-cancer agents to treat a wide variety of solid tumors. For example, cisplatin is utilized in 32 of 78 oncology regimens.¹ Platinum drug therapies could be expanded in clinical practice if dose-limiting toxicities and drug resistance could be overcome. Blend has created platinum drugs with a novel mechanism, and the potential to reduce cancer-cell resistance and side effects, expanding on the impressive track record of platinum drugs.  

¹Martindale: The Complete Drug Reference, 35th edn, 2007